MICHAEL REESE RESEARCH AND EDUCATI… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1991

Legal Domicile

Principal Officer

JASON ROTHSTEIN

Phone

3128686096

Tax Period

2023-09-01 to 2024-08-31

MICHAEL REESE RESEARCH AND EDUCATION FOUNDATION, founded in 1991, is a community nonprofit in the Medical Research sector that reported $2.6M in total revenue in fiscal year 2023. Net assets of $13.9M represent 64 months of operating reserves.

Mission

THE RESEARCH AND EDUCATION FOUNDATION CONDUCTS MEDICAL RESEARCH, EDUCATION, AND COMMUNITY SERVICES FOR VARIOUS AREAS OF MEDICINE INCLUDING, BUT NOT LIMITED TO, ONCOLOGY RESEARCH, CARDIOVASCULAR RESEARCH, AND HEALTHCARE DELIVERY.

Program Service Accomplishments

Program 1

Expenses: $1,507,217

HIV CARETHE HIV CARE PROGRAM PROVIDES INTEGRATED PRIMARY AND MULTI-SPECIALTY CARE, ADHERENCE EDUCATION, CASE MANAGEMENT, SUBSTANCE ABUSE SERVICES, MENTAL HEALTH CARE AND PREVENTION INTERVENTIONS FOR...

Program 2

Expenses: $356,381

WOMEN'S HEALTHTHE WOMEN'S HEALTH PROGRAM PROVIDES FREE SCREENING MAMMOGRAMS AND CERVICAL SCREENINGS AS WELL AS DIAGNOSTIC FOLLOW-UP SERVICES TO UNINSURED WOMEN, REGARDLESS OF INCOME. FOR WOMEN WHO...

WOMEN'S HEALTHTHE WOMEN'S HEALTH PROGRAM PROVIDES FREE SCREENING MAMMOGRAMS AND CERVICAL SCREENINGS AS WELL AS DIAGNOSTIC FOLLOW-UP SERVICES TO UNINSURED WOMEN, REGARDLESS OF INCOME. FOR WOMEN WHO ARE DIAGNOSED WITH BREAST OR CERVICAL CANCER, SURGERY, TREATMENT, MEDICATIONS AND RECONSTRUCTIVE BREAST SURGERY ARE ALSO PROVIDED.

Program 3

Revenue: $7,133,105

340B DRUG PURCHASING PROGRAM - THE FOUNDATION ENTERED INTO AN AGREEMENT WITH A THIRD PARTY TO FACILITATE THE PARTICIPATION IN THE 340B DRUG PURCHASING PROGRAM WITHOUT THE NEED TO ESTABLISH AND...

340B DRUG PURCHASING PROGRAM - THE FOUNDATION ENTERED INTO AN AGREEMENT WITH A THIRD PARTY TO FACILITATE THE PARTICIPATION IN THE 340B DRUG PURCHASING PROGRAM WITHOUT THE NEED TO ESTABLISH AND OPERATE ITS OWN PHARMACY. OUTPATIENTS OF THE CLINICS WHO ARE ELIGIBLE CAN PURCHASE OR RECEIVE COVERED 340B DRUGS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $1,502,980

Program Service Revenue $0

Investment Income $-274,573

Other Revenue $1,367,365

TOTAL REVENUE $2,595,772

Expense Breakdown

Grants Paid $228,100

Salaries & Benefits $825,516

Fundraising Expenses $0

Program Expenses $2,168,665

Other Expenses $1,788,766

TOTAL EXPENSES $2,842,382

Year-over-Year Comparison

	2023	2022	Change
Revenue	$2,595,772	$2,475,281	+0.0%
Expenses	$2,842,382	$2,717,002	+0.0%
Net Income	$-246,610	$-241,721	+0.0%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$46,159

Total Directors

$86,079

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ARTHUR MOSWIN MD	DIRECTOR	10.00	Director	$14,960	$0	$14,960
SANDRA WILKS RN	DIRECTOR	8.00	Director	$24,960	$0	$24,960
WILLIAM CHAMBERLIN MD	DIRECTOR, CHAIRMAN	1.00	Officer Director	$0	$0	$0
DENNIS LEVINSON MD	DIRECTOR, TREASURER	1.00	Officer Director	$0	$0	$0
ALAN SCHWARTZPHD	DIRECTOR	0.50	Director	$0	$0	$0
DAVID B LIEB MD	DIRECTOR	0.50	Director	$0	$0	$0
ALAN JACKSON MD	DIRECTOR	0.50	Director	$0	$0	$0
MARK C SHIELDS MD	DIRECTOR	0.50	Director	$0	$0	$0
DONNA THOMPSON	DIRECTOR	0.50	Director	$0	$0	$0
AUDREY TATAR MC	DIRECTOR	0.50	Director	$0	$0	$0
GABRIELA ILLA	DIRECTOR	0.50	Director	$0	$0	$0
JASON ROTHSTEIN-9123	EXECUTIVE DIRECTOR	40.00	Officer Director	$46,159	$0	$46,159
LYNN P VOCELKA	ASSOC DIRECTOR	40.00	Highest	$132,733	$0	$132,733
HONG DENG	NURSE CASE MANAGER	40.00	Highest	$103,648	$0	$103,648
WILLIAM CLARKPHD-THRU 83123	FORMER EXECUTIVE DIRECTOR	40.00		$144,297	$3,460	$147,757

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$2,595,772	$2,842,382	$15,652,009	$-246,610
2023	$2,475,281	$2,717,002	$15,191,603	$-241,721
2022	$2,875,263	$3,224,652	$14,498,150	$-349,389
2021	$3,650,987	$4,465,099	$25,901,146	$-814,112
2020	$2,629,756	$2,289,517	$19,607,273	$340,239
2019	$2,862,420	$2,817,342	$14,240,334	$45,078
2018	$3,402,120	$3,118,738	$13,715,902	$283,382

MICHAEL REESE RESEARCH AND EDUCATION FOUNDATION